Abstract
During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.
Keywords: Inflammation, anti-inflammatory drug, p38 MAPK, IL-6, JAK/STAT, PI3K, hippo pathway.
Current Pharmaceutical Design
Title:Signaling Pathways in Inflammation and Anti-inflammatory Therapies
Volume: 24 Issue: 14
Author(s): Yiu To Yeung, Faisal Aziz, Angelica Guerrero-Castilla and Sandro Arguelles*
Affiliation:
- Department of Physiology, Faculty of Pharmacy, University of Seville, Seville,Spain
Keywords: Inflammation, anti-inflammatory drug, p38 MAPK, IL-6, JAK/STAT, PI3K, hippo pathway.
Abstract: During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.
Export Options
About this article
Cite this article as:
Yeung To Yiu , Aziz Faisal, Guerrero-Castilla Angelica and Arguelles Sandro *, Signaling Pathways in Inflammation and Anti-inflammatory Therapies, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180327165604
DOI https://dx.doi.org/10.2174/1381612824666180327165604 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Executive Editor
Current HIV Research Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Role of Gut Microbiota in Human Health and Diseases
Current Nutrition & Food Science Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Current Molecular Medicine Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review)
Current Genomics Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Understanding Nutritional Interventions and Physical Exercise in Non-Alcoholic Fatty Liver Disease
Current Molecular Medicine When Does Food Refusal Require Professional Intervention?
Current Nutrition & Food Science Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Platelet Function in Inflammatory Diseases: Insights from Clinical Studies
Inflammation & Allergy - Drug Targets (Discontinued) The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Phytosterols: Perspectives in Human Nutrition and Clinical Therapy
Current Medicinal Chemistry Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion
Current Pharmaceutical Design